Dergiler / The Anatolian Journal of Cardiology / 2018 / Cilt: 20 - Sayı: 1

Analysis of gene copy number variations in patients with congenital heart disease using multiplex ligation-dependent probe amplification

Sayfa
9–15
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The CNVs were confirmed using fluorescence in situ hybridization.Conclusion: Our study confirmed that the analysis of recurrent CNVs using the MLPA assay within pediatric cardiology clinics can led to an earlysyndrome diagnosis in nonsyndromic patients with CHD.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: At the molecular and cellular levels, heart development entails the precise orchestration of genetic events such as the interplay ofmaster transcriptional regulators, signaling pathways, and chromatin remodeling.
📊
Temel Bulgular & Veri:Recent studies among patients with congenital heart disease(CHD) have shown the importance of recurrent copy number variations (CNVs) in a significant number of patients.
💡
Sonuç & Katkı:The CNVs were confirmed using fluorescence in situ hybridization.Conclusion: Our study confirmed that the analysis of recurrent CNVs using the MLPA assay within pediatric cardiology clinics can led to an earlysyndrome diagnosis in nonsyndromic patients with CHD.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: At the molecular and cellular levels, heart development entails the precise orchestration of genetic events such as the interplay ofmaster transcriptional regulators, signaling pathways, and chromatin remodeling. Recent studies among patients with congenital heart disease(CHD) have shown the importance of recurrent copy number variations (CNVs) in a significant number of patients. Recurrent CNVs that spanseveral genes may affect other important organs, besides the heart. Because CHD may be the first presenting symptom in such patients, theanalysis of recurrent CNVs in the genomic regions containing genes associated with CHD in patients referring to cardiology clinics may lead toan early diagnosis and the treatment of extracardiac symptoms in these patients. In this study, we aimed to screen CNVs of genomic regionsincluding GATA4, NKX2-5, TBX5, BMP4, and CRELD1 genes and to analyse the 22q11.2 chromosomal region in apparently nonsyndromic patientswith cardiac septal defects.Methods: Genomic regions including GATA4, NKX2-5, TBX5, BMP4, and CRELD1 genes and the 22q11.2 chromosomal region were analyzed inapparently nonsyndromic 45 patients with cardiac septal defects using the MLPA P-311 A2 Congenital Heart Disease kit. Multiplex ligationdependentprobe amplification (MLPA) is an established technique for the detection of known CNVs. MLPA is substantially less expensive thanarray CGH and is relatively simple to use for clinicians without specific expertise in genomic technology; thus, MLPA could be used as a first-tierscreening assay.Results: We screened 45 patients with cardiac septal defects for CNVs using the MLPA P-311 A2 kit. We identified three CNVs (n=3/45, 6.66%)and three 22q11 deletions. The CNVs were confirmed using fluorescence in situ hybridization.Conclusion: Our study confirmed that the analysis of recurrent CNVs using the MLPA assay within pediatric cardiology clinics can led to an earlysyndrome diagnosis in nonsyndromic patients with CHD.

🔖

Bu Makaleye Atıf Yap

MUTLU, E. T. M., AYKAN, H. H., KARAGÖZ, T. (2018). Analysis of gene copy number variations in patients with congenital heart disease using multiplex ligation-dependent probe amplification. The Anatolian Journal of Cardiology, Cilt: 20 - Sayı: 1, 9–15. https://ajindex.com/articles/365302

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Breckpot J, Thienpont B, Arens Y, Tranchevent LC, Vermeesch JR, Moreau Y, et al. Challenges of interpreting copy number variation in syndromic and non-syndromic congenital heart defects. Cytogenet Genome Res 2011; 135: 251-9. [CrossRef] Lu XY, Phung MT, Shaw CA, Pham K, Neil SE, Patel A, et al. Genomic imbalances in neonates with birth defects: High detection rates by using chromosomal microarray analysis. Pediatrics 2008; 122: 1310-8.
  2. Tsirikos AI, Khan LA, McMaster MJ. Spinal deformity in patients with DiGeorge syndrome. J Spinal Disord Tech 2010; 23: 208-14.
  3. Schneider M, Debbané M, Bassett AS, Chow EW, Fung WL, van den Bree M, et al.; International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry 2014; 171: 627-39. [CrossRef] Cheung EN, George SR, Andrade DM, Chow EW, Silversides CK, Bassett AS. Neonatal hypocalcemia, neonatal seizures, and intellectual disability in 22q11.2 deletion syndrome. Genet Med 2014; 16: 40-4. [CrossRef] Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 2007; 370: 1443-52. [CrossRef] Oskarsdóttir S, Holmberg E, Fasth A, Strömland K. Facial features in children with the 22q11 deletion syndrome. Acta Paediatr 2008; 97: 1113-7. [CrossRef] Monteiro FP, Vieira TP, Sgardioli IC, Molck MC, Damiano AP, Souza J, et al. Defining new guidelines for screening the 22q11.2 deletion based on a clinical and dysmorphologic evaluation of 194 individuals and review of the literature. Eur J Pediatr 2013; 172: 927-45.
  4. Bassett AS, McDonald-McGinn DM, Devriendt K, Digilio MC, Goldenberg P, Habel A, et al.; International 22q11.2 Deletion Syndrome Consortium. Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 2011; 159: 332-9. [CrossRef] Borgmann S, Luhmer I, Arslan-Kirchner M, Kallfelz HC, Schmidtke J. A search for chromosome 22q11.2 deletions in a series of 176 consecutively catheterized patients with congenital heart disease: no evidence for deletions in non-syndromic patients. Eur J Pediatr 1999; 158: 958-63. [CrossRef] Rauch A, Hofbeck M, Leipold G, Klinge J, Trautmann U, Kirsch M, et al. Incidence and significance of 22q11.2 hemizygosity in patients with interrupted aortic arch. Am J Med Genet 1998; 78: 322-31.
  5. Boudjemline Y, Fermont L, Le Bi